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ABSTRACT 
 
Background: Cerebrovascular stroke (CVS) is the third leading most common cause of death in the world. Role of 
antihypertensive drugs and nitric oxide donors such as glyceryl trinitrate (GTN) in acute ischemic cerebrovascular stroke 
varies in their effects on cerebral autoregulation (CA). Assessment of biochemical marker as S100β protein is an 
important diagnostic tool. Objective: The aim of this study is to assess the role of transdermal glyceryl trinitrate (GTN) 
patch in the management of acute ischemic CVS and to evaluate the role of S100β protein as a prognostic marker in acute 
ischemic CVS. Methods: Forty acute ischemic CVS patients with hypertension were included. They were divided in to 
two groups, Group (A); 20 patients maintained on their anti-hypertensive treatment, and Group (B); 20 patients received 
GTN nitro dermal patch 5mg. All cases were subjected to, clinical evaluations by European stroke scale, assessment of 
S100β on third day and after 14 days of stroke onset and brain CT. Results: There was no significant statistical difference 
between patient groups as regard clinical stroke evaluation on third day on stroke onset but there was significant statistica l 
difference between group (A) and (B) after 14 days of stroke. There was highly significant statistical difference in the 
serum level of S100β in group (A) and (B) on third day of stroke onset. Conclusion: Using GTN nitro dermal patch is a 
promising solution in management of hypertension in acute ischemic CVS and S100β may help in the prediction of its 
prognosis. [Egypt J Neurol Psychiat Neurosurg.  2014; 51(2): 153-158] 
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INTRODUCTION 
 
Cerebrovascular stroke (CVS) remains a major 
cause of long-term disability. Hypertension presents in 
more than 75 % of patients at presentation with acute 
ischemic stroke.1  
Cerebral autoregulation (CA) is defined as the 
ability of the brain to maintain relatively constant CBF 
despite changes in cerebral perfusion pressure (CPP).2 
CA is impaired in the presence of moderate to severe 
cerebral ischemia.3 Calcium channel blocker is one of 
antihypertensive drugs which reduces cerebral 
perfusion in parallel with their effect on blood 
pressure (BP).4 Angiotensin modifying drugs, such as 
captopril and perindopril (angiotensin-converting 
enzyme inhibitors) and losartan (angiotensin receptor 
antagonist) did not seem to alter cerebral blood flow 
(CBF) or middle cerebral artery blood velocity.5  
Similarly, nitric oxide donors such as sodium 
nitroprusside and glyceryl trinitrate (GTN) maintain 
regional cerebral blood flow.6 It was further shown that 
the  administration  of  a  vasodilating  agent  would often 
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dilate vessels in normal regions and shunt blood from the 
ischemic area. This paradoxical phenomenon is called the 
intracerebral steal. Thus significant reductions in BP after 
transdermal GTN are not associated with changes in CBF 
or cerebral perfusion pressure or cerebral steal in patients 
with recent stroke, this renders it an important agent in 
management of acute ischemic cerebrovascular stroke.7  
At present, the absence of a widely available and 
sensitive diagnostic laboratory test for acute cerebral 
ischemia remains a significant limitation in the 
diagnosis and prediction of outcome of stroke. The 
evaluation of blood-borne biochemical markers of 
tissue injury appears recently as a new diagnostic and 
prognostic tool.8 Several monitoring techniques have 
been developed based on measuring the levels of 
various proteins, including neuron specific enolase, 
myelin basic protein, glial fibrillary acidic protein, and 
S100 protein.9 
S100 protein is an acidic calcium-binding 
protein, its molecular weight is 21,000μg, and it 
constitutes a major component of the cytosol, 
predominantly in astroglial cells. It was termed S100 
because it is partially soluble in a 100% saturated 
solution of ammonium sulfate. The protein consists of 
two subunits ( and ). S100α is found in striated 
muscles, kidneys and heart and S100β is found in high 
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concentration in glial and schwann cell. Elevations of 
S100β in cerebospinal fluid (CSF) and serum were 
reported in various forms of acute brain damage. 
Concentration of S100β in CSF is a sensitive marker 
of brain damage after head trauma, cerebral hypoxia, 
cerebral bleeding and ischemic stroke.10 
Post stroke S100β serum concentrations were 
reported to correlate significantly with the size of 
infarcted brain areas. As it is released from dead 
astroglail cells followed by a leakage of the protein 
through an impaired blood-brain barrier. The peaks of 
S100β serum levels were observed at the second and 
the third days after stroke onset.11 
Aim of work: to assess the role of transdermal 
GTN patch in the management of acute ischemic 
cerebrovascular stroke patients with hypertension and 
to evaluate the role of S100β protein as a prognostic 
marker, in the patients groups in correlation with 
clinical and radiological evaluation. 
 
SUBJECTS AND METHODS 
 
This is case control study included 40 patients 
with acute cerebrovascular ischemic stroke and 
hypertension, 18 of them are males and 22 are females 
with mean age ±SD (57.65±12.16). Patients were 
divided into two groups 20 patient maintained on their 
antihypertensive treatment group (A) and 20 patient 
received GTN nitrodermal patch 5mg. Group (B). 
Patients were selected from the inpatient of neurology 
department, outpatient clinic and emergency room 
department of Al-Zahraa University Hospital. Healthy 
20 subjects of matched age and sex are selected to act 
as a control group. 
We excluded those suffering from previous 
cerebrovascular stroke, recent acute infection, 
collagen disorders, hematological disorders, liver and 
renal diseases, myocardial infarction, unstable angina, 
left ventricular failure and contraindication to nitrate 
therapy. 
All patients were submitted to the following: full 
medical history and general medical examination, 
neurological assessment including history and 
complete neurological examination, evaluation of 
stroke by European stroke scale to assess the 
neurological deficit. This scale was done within 
48hours from the onset of stroke and repeated after 14 
days for each patient to detect the prognostic outcome 
of stroke, as regard group B they received GTN 
nitrodermal patch 5mg for 16 hour daily then removed 
8 hours for 6 days, follow up of blood pressure for 
both groups, routine laboratory investigations, 
assessment of laboratory biomarkers; serum S100β on 
the third day and repeated after14 days of stroke onset 
and assay of S100β protein was done by Enzyme 
Linked Immunosorbant assay kit (ELISA) and brain 
computed axial tomography (CT) (Philips Tomoscan 
LX); it was done for all patients within 48hours from 
the onset of stroke and repeated after 14 days. It was 
done to detect; type of stroke (ischemic only), site of 
the lesion and size of the lesion. 
 
Statistical Analysis 
The data were collected, coded and SPSS 
(statistical package for social science), windows version 
11.5 was used for analysis. Data were expressed as 
number and mean ±standard deviation (SD). We also 
used analysis of variance (ANOVA); a single test used to 
collectively indicate the presence of any significant 
difference between several groups (several arithmetic 
means). Quantitative data were analyzed by using student 
t-test of significance. Correlation coefficient (r) test to 
correlate between the data of the different groups.  
P<0.05 is considered significant and p<0.001 is 
considered highly significant. 
 
RESULT 
 
This study was conducted on 40 patients (18 male 
and 22 female) the mean of their age was 57.65±12.16, 
divided into two groups.  Group (A); 20 patient 
maintained on their antihypertensive treatment. Group 
(B); 20 patient received GTN nitrodermal patch 5 mg. 
There was no significant statistical difference 
between patients used antihypertensive drugs (group A) 
and patients used GTN patch (group B) as regard clinical 
stroke evaluation according to European stroke scale   
on the third day of stroke onset (p value >0.05) but there 
was significant statistical difference between group A&B 
after 14 days of stroke onset it was better in group B than 
group A (p value <0.05) (Table 1). 
There was decrease in mean arterial BP (MAP) 
in patient used antihypertensive drugs group A as well 
as in those using GTN patch group B. The decrease 
was more in patient used GTN patch than those 
maintained on their antihypertensive drugs but of no 
significant statistical difference (p value >0.05) (Table 2). 
There was highly significant statistical difference as 
regard the level of S100β between patient groups and 
control group (p<0.001) (Table 3). 
There was highly significant statistical difference 
in the serum level of S100β in group A and B of 
patients in comparison with control group on 3rd day 
and after 14 days of stroke onset (p value <0.001). 
Also there was highly significant statistical difference 
in the serum level of S100β between group A and  
group B on 3rd day  of stroke onset (p value <0.001) 
but there was no significant statistical difference in the 
serum level of S100β between group A and  group B 
after 14 days of stroke onset (p value >0.05) (Table 4). 
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There was significant statistical difference 
between means  of S100β in different sites of insults it 
was higher in subcortical regions  then capsular then 
brain stem and the lower level was in the lacunar 
stroke (p value <0.05) (Table 5). 
There was significant statistical difference 
between group A and B as regard the size of infarction 
was larger in group A than group B (p value <0.05), 
also there was significant statistical difference 
between group A and B as regard outcome of stroke 
(the European stroke scale after 14 days) it was better 
in group B than in group A (P value <0.05) (Table 6). 
There was a highly significant positive 
correlation between the level of S100β and the size of 
infarction at the 3rd and 14th days of stroke onset in the 
patient groups (p<0.001) (Table 7). 
  
Table 1. European stroke scale results of patient groups (A and B) according to the time of examination. 
 
 
G(A) G(B) Independent t-test 
Range Mean ±SD Range Mean ±SD t P-value 
European scale (on 3rd day) 54 - 93 80.1 10.99 75 - 90 83.9 4.79 1.418 0.164 
European scale( 14th day) 70 - 100 89.6 7.24 80 - 98 94.65 4.89 2.585 0.013* 
*Significant at p<0.05 
 
Table 2. Comparison between patient groups (A and B) as regard BP. 
 
Variable 
Group A Group B Independent t-test 
Mean ±SD Mean ±SD t P-value 
Day 1 117.32 14.13 113.18 13.62 0.941 0.353 
Day 2 113.49 10.29 106.93 16.54 1.506 0.140 
Day 3 108.59 12.70 104.63 13.84 0.943 0.352 
Day 4 105.74 13.06 106.36 16.25 0.133 0.895 
Day 5 107.19 13.75 106.80 21.59 0.068 0.946 
Day 6 109.89 9.20 101.46 18.23 1.845 0.073 
 
Table 3. The level of S100β in the studied patient groups versus the control group. 
 
Groups 
S100β Independent t-test 
Mean SD Range t P-value 
Patient groups 524.13 120.37 350 – 842 16.939 0.000* 
Control group 65.2 11.72 48 – 90 
*Significant at p<0.01 
 
Table 4. Comparison between patient groups A and B and control group as regard S100β in the 3rd day and after 14 days of 
stroke onset. 
 
Variable 
Group A 
Antihypertensive 
Group B 
GTN patch 
Control 
P-value 
Mean ±SD Mean ±SD Mean ±SD 
S100β 3rd day (ng/L) 574.75 128.8 473.5 88 65.2 11.7 p1 < 0.001* 
p2 < 0.001* 
p3 < 0.001* 
S100β 14th day (ng/L) 317.6 137 347.2 65.6 65.2 11.7 p1 > 0.05 
p2 < 0.001* 
p3 < 0.001* 
*Significant at p<0.01, p1: Comparison between Antihypertensive group and GTN group, p2: Comparison between Antihypertensive 
group and Control group, p3: Comparison between GTN group and Control group 
 
Table 5. Comparison between the level of S100β and site of infarction in patient groups. 
 
Site  
S100β One-Way ANOVA 
Mean ±SD F P-value 
Cortical-Subcortical 582.40 161.31 3.211 0.002* 
Capsular 565.78 133.29 
Lacunar 472.44 66.50 
Brain stem 456.00 10.58 
* Significant at p<0.01 
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Table 6. Comparison between patients groups A and B as regard size of infarction, European stroke scale after 14 days 
of stroke onset. 
 
Variable 
Group A  Group B Independent t-test 
Mean ±SD Mean ±SD t P-value 
CT-scan 14th day (cm) 1.77 0.65 1.09 0.71 2.234 0.038* 
European scale at 14th day 89.47 7.21 95.65 4.82 -2.253 0.036* 
* Significant at p<0.05 
 
Table 7. Correlation between the level of S100β and the size of infarction among patient groups (A and B) on the 3rd 
and 14th days of stroke onset. 
 
Variable 
Size of infarction 
r P-value 
S100 at 3rd day ( ng/L) 0.799 0.000* 
S100β at 14th day (ng/L) 0.899 0.000* 
* Significant at p<0.01 
 
 
DISCUSSION 
 
The management of high BP in acute ischemic 
stroke is highly controversial because of a lack of reliable 
evidence from randomized, controlled trials. In spite of 
the controversy, the evidence that blood pressure in acute 
stroke should be treated when it is very high level.12  
There was no significant statistical difference 
between patients used GTN patch (group A) and patients 
used other antihypertensive drugs (group B) as regard 
clinical stroke evaluation by European stroke scale on 
the third day of stroke onset but there was significant 
statistical difference between group A and B after 14 
days of stroke onset.  
This can be explained that GTN nitrodermal patch 
act as anti-inflammatory through oxygen free radicle 
activation and it is not associated with changes in CBF or 
cerebral perfusion pressure or cerebral steal in patients 
with recent stroke.7 
Our study found that GTN is useful in the 
control of hypertension during acute stage of stroke 
than other antihypertensive drugs, there was decrease 
in the MAP in both groups but it was more in patients 
used GTN (group B) than those used various types of 
antihypertensive drugs (group A). The current study 
found that the decrease of BP was more in the 2nd and 
6th day of stroke, with good outcome of patients 
according to European stroke scale. 
Our findings are in partial agreement with Philip 
and colleagues13 who stated that GTN significantly 
lowered BP by 13.0/5.2 mmHg at day 1 and 9.3/5.0 
mmHg at day 8. The lesser reduction at day 8 than day 
1 can be explained by tolerance to GTN was 
developing. This result agrees with Ankolekar and 
colleagues14 who reported that GTN might be 
beneficial if given very early after stroke.  
However, this result disagrees with Schrader and 
colleagues15 who stated that BP in the first week and 
functional status at onset of stroke and at 3 months 
were similar between treatment and placebo groups. 
This can be explained by the difference in the 
selection of patient groups.  
Schrader and colleagues15 explained his results 
by that acute ischemic stroke, is associated with 
dysfunctional cerebral autoregulation so that cerebral 
perfusion becomes dependent on systemic BP. 
However, GTN release NO, which is a potent 
modulator of cerebrovascular reactivity, especially in 
collateral vessels.16 Vascular nitric oxide levels are 
low in stroke, so collateral vessels may not be 
maximally dilated. Hence, CBF might be held 
constant with GTN if moderate reductions in systemic 
BP were counterbalanced by increases in collateral 
blood supply, which would be potentially beneficial in 
acute stroke.17  
Our mean value of S100β is highly significant in 
patients groups than control because it is sensitive 
marker of brain damage.10 
Our samples are collected within the first three days 
of stroke onset because the peaks of S-100β serum levels 
were observed at days 2 and 3 after stroke onset.18 A 
possible explanation for this gradual increase could be 
that cellular injury resulting from cerebral ischemia is 
a gradual process.19  
Our results agree with that of Foerch and 
colleagues20 who stated that S100 measurements 
between 12 and 24 h after stroke onset predict a size 
of infarction with the highest degree of accuracy. 
In our study there was significant statistical 
difference between means of S100β as regard sites of 
insults it was higher in cortical subcortical regions then 
capsular then brain stem and the lower level was in the 
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lacunar stroke. These results was in agreement with 
Kim and colleagues21 who reported non-measurable 
S100 concentrations in patients with small subcortical 
lesions, and this is consistant largely with our study in 
patients with lacunar infarction who had normal levels 
of serum S100 subunit and who improved markedly 
and showed excellent clinical improvement on basis of 
neurological and functional outcome. 
In our study, there was a highly significant 
statistical positive correlation between S100β and the 
size of infarction at the 3rd day and after 14 days of 
stroke onset in the patient groups A and B. This is 
explained by the presence of S100β in serum is the 
consequence of combined leakage out of necrotic glial 
cells and passage through an impaired blood-brain 
barrier, indicating severe ischemic cell injury. Large 
infarction zones generally lead to serious neurological 
deficits in the acute stage of stroke and severe 
functional impairment.19  
Our findings are in agreement with Brea and 
colleagues11, who reported that serum S100 levels 
are significantly raised in patients with ischemic 
stroke and haemorrhagic stroke; S100 levels are 
significantly related to infarct size and clinical 
outcome. 
 
Conclusion 
Our study showed that GTN patch can be useful as 
an antihypertensive medication for the hypertensive 
patients who developed acute ischemic cerebrovascular 
stroke. Added to its antihypertensive effect, it can 
improve the clinical scales and the size of infarction in 
those patients. The serum level S100β was positively 
correlated with the size of infarction adding an indirect 
laboratory confirmation for the promising role of GTN 
patch in acute ischemic cerebrovascular stroke. Further 
studies are warranted to investigate the role of GTN patch 
in the management of hemorrhagic cerebrovascular 
stroke. Nevertheless, single S100 obtained 48 and 72 
hours after ischemic stroke onset could be applied as an 
easily accessible and valid surrogate marker to evaluate 
the size of infarction and monitor the effect of GTN patch 
or any other future antihypertensive medications to be 
used in acute cerebrovascular stroke.  
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 الملخص العربى
 
 بيتا في مرضي السكتة الدماغية الإرتوائية الحادة المصابون بارتفاع ضغط الدم 110تقييم دور بروتين إس 
 
ةرر  ةاطرر  سكترراتد سكية ثاررد  ٪75ساتفرر ض طررلد سكرري  سكةت ررتي برر  ياكررا ةرر   تعتبررا سكترراتد سكية ثاررد ك كررب يابررا ترربو اررفي  لكرر  سكتبرر   برر  سكعرر ك  تاعتبررا
 سكح ي  ة  يه  سلأتب و سكت  تاتبد بشال ةتتقل بقلد نتبد سكتحت  تتااسا سكح كد ب  تقت ةباا.سلإاتتسئاد 
 تقي ت ي ي  سكعق قاا سكت  تخفض طلد سكي  ب  ةاط  سكتاتد سكية ثاد سكح ي  تختلف ب  تأكااه  عل  تيبق سكي  لك  سكةخ. 
سك لت ا  عبا سك لي كتقلال طلد سكي  يكنر   سكتراتد سكية ثارد سكحر ي  تةر  اصر حو  تقي ق ةت بعض سلأبح ب بياستد ةيى ب علاد لاصقد كلاك  نتاست
 ذكك ة  تلااست ب  سلإةيسي سكيةتى كلةخ.
باتر  بر   110تقي بازت يهةاد ساتش ف ة ةتعرد ةر  سكريلالات سكةعةلارد كتشرخاك سكتراتد سكية ثارد تةريى تأكااهر  علر  خلاار  سكةرخ ةكرل براتتا  ل  
 . ثاد حاب ينه اةكل يحي سكيلالات سكح تةد سكت اعد تسكيقاقد سكت  تعبا بيقد ع  ح   سلإص بدةاط  سكتاتد سكية
ة  ةاط  سكتاتد سكية ثاد سلإاتتسئاد سكح ي  سكةص بت  ب اتف ض طلد سكي . تكقي ت  تقتا  سكةاط   10سكياستد عل   ل اس كقي ت   :العينة وطرق البحث
سكطلد سكةختلفد، ة ةتعد (و) عشات  ة  سكةاط  اع ك ت  ب تتخيس  لاصقد  بأيتادة  سكةاط  اع ك ت   10 ة ةتعد (ي) يت تاتا سك  ة ةتعتا  
 .سلأصح  كلاك  نتاست سك لت ا ، تة ةتعد ط بدد تتشةل عشات  ة  
 . سكفحتك سكةخب اد سكاتتاناد. سكت  اخ سكدب  سكا ةل، تسكفحك سكدب  سكع   ت سكفحك سكعصب تقي خطع  ةاع سلأباسي لك  ة  ال : أساليب البحث:
 ةقدعاد عل  سكةخ. يشعدبات  ب كي  ب  سكات  سكك كب تسكات  سكاسبع عشا ة  حيتب سكتاتد سكية ثاد. 110نتبد باتتا  ل  
 :سلآتادسكياستد سكنت ئج  يبازتتكقي 
بيت  ي  ترأكاا علر  تريبق سكري  لكر  سكةرخ يت زار ي   ي  لاصقد كلاك  نتاست سك لت ا  تخفض طلد سكي  ب  سكتاتد سكية ثاد سلإاتتسئاد سكح ي   
 .يعاسض سكتاتد سكية ثاد تذكك ب كةق اند بأيتاد سكطلد سلأخا 
 قري ت رري ي  ةرركل سكترراتد سكية ثاررد سلإاتتسئاررد سكحرر ي  ارر   يبطررل برر  سكةاطرر   سكررذا  قرر ةتس ب تررتخيس  لاصررقد كلاكرر  نترراست سك لترر ا  ب كةق انررد 
 اد سكطلد سلأخا  .  ب كذا  ق ةتس ب تتخيس  ييت 
باترر  ب كرري  تح ر  سك لدررد سكةخاررد برر  سلأشررعد سكةقدعاررد برر  سكاررت  سكك كررب تسكاررت  110علاقررد داياررد تسطررحد بررا  ةتررتت  برراتتا  ل   ينره ات رري 
 سكاسبع عشا ة  حيتب سكتاتد سكية ثاد سلإاتتسئاد سكح ي .
